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Abstract 
The objective of this study is to investigate the characteristics and the evolution of visual field damage caused by 
Leber’s hereditary optic neuropathy (LHON) and to provide clinical data for the diagnosis of LHON. Parameters of 
visual field in 32 consecutive patients (49 eyes) with LHON who were confirmed by genetic diagnostic tests were ret-
rospectively measured within 1 week, between three to six months, and at six months after onset. Visual field defects 
revealed central scotoma in 26 eyes (53.1 %), paracentral scotoma in 12 eyes (24.5 %), ceco-central defects in 6 eyes 
(12.2 %), blind spot enlargenment in 3 eyes (6.1 %), quadrantanopia in 2 eyes (4.1 %) within 1 week after onset. After 
3 to 6 months, ceco-central defects were detected in 22 eyes (44.9 %), central isopter constriction in 10 eyes (20.4 %), 
hemianopia or quadrantanopia in 5 eyes (10.2 %), central scotoma in 4 eyes (8.2 %), and paracentral scotoma in 1 
eye (2.0 %). After 6 months, central isopter constriction was observed in 18 eyes (36.7 %), diffuse defects in 21 eyes 
(42.9 %), ceco-central defects in 3 eyes (6.1 %), hemianopia or quadrantanopia in 5 eyes (10.2 %), and central scotoma 
in 2 eyes (4.1 %). LHON at different stages was characterized by different focal visual field defects: visual field defects 
in LHON patients within 1 week after onset were mostly central or paracentral scotoma, which was enlarged around 
the ceco-central defect, or connected to form a blind spot after 3–6 months. Diffuse and central isopter constriction 
defects were usually developed after 6 months. Damages firstly appeared in papillomacular bundle and gradually 
expanded outward. These characteristics of visual field defects reported in this study might provide a clinical basis for 
better diagnosis of LHON.
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Background
Leber’s hereditary optic neuropathy (LHON) has a mito-
chondrial inheritance pattern. In 91–92  % of cases in 
mainland and Taiwan of China, the disease is associated 
with G11778A mitochondrial DNA (mtDNA) mutations 
(Lin et al. 2012; Wang et al. 2005). LHON typically affects 
young adult males who have the gene mutation present-
ing unilateral or bilateral subacute/acute painless loss of 
central vision. The disease has usually entered middle or 
late phase when diagnosed (Hilo et  al. 2013; Man et  al. 
2002; Vergani et al. 1995).
In the early stage of the disease, the unmyelinated reti-
nal nerve fibre layer of optic nerve is firstly affected, espe-
cially the papillomacular bundle. With the development 
of the disease, the entire nerve fibre is affected and optic 
atrophy ensues. According to the evolution of LHON, the 
visual field defects is also typical. Firstly, there is a ceco-
central defect, and then a larger central defect, often with 
a superior or inferior predilection (Wallace et  al. 1988; 
Yu-Wai-Man et al. 2009).
We have previously conducted a few studies on the 
development of effective gene therapies for the treat-
ment of LHON (Cui et al. 2013; Pei et al. 2013; Shi et al. 
2012; Yang et al. 2015). In this retrospective study, visual 
field for 32 patients (49 eyes) with LHON who were con-
firmed by genetic diagnostic tests were measured within 
1 week, between three to six months, and at six months 
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after onset to investigate the characteristics of visual field 




A total of consecutive 32 patients (49 eyes) who were 
diagnosed as LHON by mtDNA analysis between Janu-
ary 2013 and July 2015 in the Department of Ophthal-
mology, Tongji Hospital, Tongji Medical College at the 
Huazhong University of Science and Technology, China 
were selected in this study. The study was a retrospec-
tive design and was approved by the ethics committee 
in Tongji Hospital at the Tongji Medical College, and 
performed strictly following the provisions of the Dec-
laration of Helsinki. Visual field testing and others oph-
thalmologic examinations including slit-lamp, BCVA, 
intraocular pressure, and fundus examination of all 
patients were reviewed. Professor Ni evaluated the dis-
ease stage for each patient as previously described (Niko-
skelainen et al. 1984). Disease were categorized into three 
stages: onset (within a week), middle stage (between 3 
and 6 months), and late stage (over 6 months), the aver-
age time of the 3groups were 0.13  ±  0.06, 4.4  ±  0.88, 
10.47  ±  3.4  m respectively. Eyes with intraocular pres-
sure above 21  mmHg, retinal disease, unclear history, 
other optic neuropathies or no visual field damage were 
excluded. The study was a retrospective design and was 
approved by the ethics committee in Tongji Hospital at 
the Tongji Medical College, and performed strictly fol-
lowing the provisions of the Declaration of Helsinki.
Visual field examination
Visual field examination was performed using HFAII740 
(Humphrey Field AnalyzerII, Carl Zeiss Meditec, Dub-
lin, California, USA) by an experienced operator in a 
darkroom.
Patients received the original pupil dilation and inhib-
ited mydriasis with the following parameters: 1. the 
duration of stimulation cursor was 200 ms; 2. the bright-
ness of background light was 31.5 ASB; 3. the bright-
ness of stimulation cursor was 0.08–10,000 ASB; 4. the 
range of measurement was 0°–30° central field. A total 
of 5.76 points were measured. The following results were 
recorded: 1. fixation losses, 2. false NEG errors, 3. false 
POS errors, 4. mean defect (MD), 5. pattern standard 
deviation (PSD), 6. visual field index (VFI). Visual test 
showed that fixation loss more than 20 % and false posi-
tive or false negative errors greater than 15 % had been 
excluded. The PSD reflects the variation of light sensitiv-
ity and the local vision defects; the MD shows whether 
the light sensitivity of general visual field defects and how 
much it defects; the VFI tends to reflect the overall level 
of the central visual field. The Visual field defects were 
classified as paracentral scotoma, ceco-central defects, 
blind spot enlargenment and quadrantanopia. Ceco-
central defects were defined as isolated scotomas in the 
circular area between 0° and 10°. Paracentral scotoma 
was defined as isolated scotomas in the Bjerrum’s area 
between 5° and 25°. BCVA examinations were performed 
using an international standard visual acuity chart. The 
category of the visual field of each patient was defined by 
another doctor Zhiqi Chen, who did not know the stage 
of disease for each patients.
Statistical analysis
Data were presented as mean ± standard deviations. All 
data were analyzed using SPSS software (version13.0). 
Variations between groups were compared by post hoc 
tests. Correlations between VFI, MD and BCVA (Log 
MAR) were analyzed using Pearson correlation coef-
ficient. Characteristics of visual field damage associated 
with LHON were analyzed. p values less than 0.05 were 
considered statistically significant.
Results
A total of 32 consecutive LHON patients were selected 
for this study including 4 women and 28 men with a 
mean age of 22.8 (range: 9 to 48  years). All diagnosed 
patients were confirmed by mtDNA analysis including 29 
cases (90.6 %) of G11778A, 2 cases of G3460A, and 1 case 
of T14484C.
Sensitivity and stability of visual field
Correlations between VFI, MD and BCVA (LogMAR) 
were analyzed using Pearson correlation coefficient, It 
was found that MD was negatively correlated with BCVA 
(LogMAR) (r = −0.613, p = 0.011). VFI was also nega-
tively correlated with BCVA (LogMAR) (r  =  −0.703, 
p = 0.000). No correlation between PSD and BCVA (Log 
MAR) was detected (r = 0.102, p = 0.577) (Fig. 1). The 
visual field for 27 eyes with relatively stable BCVA (Log 
MAR) at 3 and 6  months was compared. It was shown 
that MD at 3 months was significantly lower when com-
pared with that at 6  months (p  =  0.029), whereas PSD 
(p = 0.619) and VFI (p = 0.125) at 3 months were simi-
lar to those at 6 months. The visual field of 22 eyes with 
unstable BCVA (LogMAR) was also analyzed. While MD 
(p =  0.028) and VFI (p =  0.016) at 3  months were sig-
nificantly lower than those at 6 months, PSD at 3 months 
was similar to that at 6  months (p  =  0.599). Although 
BCVA (LogMAR) has been considered as an important 
objective indicator for the evaluation of visual impair-
ment in LHON patients, VFI and MD were confirmed 
as highly sensitive and stable indicators for LHON in our 
study.
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Characteristics of visual field damage
Visual fields were analyzed by doctor chen and professor 
liin 32 patients (49 eyes) with LHON. Central scotoma was 
revealed in 26 eyes (53.1 %), paracentral scotoma in 12 eyes 
(24.5 %), ceco-central defect in 6 eyes (12.2 %), blind spot 
enlargenment in 3 eyes (6.1 %), and quadrantanopia in 2 
eyes (4.1 %) within 1 week after onset. From 3 to 6 months, 
ceco-central defect was detected in 22 eyes (44.9 %), cen-
tral isopter constriction in 10 eyes (20.4  %), hemianopia 
or quadrantanopia in 5 eyes (10.2  %), central scotoma in 
4 eyes (8.2  %), and paracentral scotoma in 1 eye (2.0  %). 
Six months later, central isopter constriction was observed 
in 18 eyes (36.7  %), diffuse defect in 21 eyes (42.9  %), 
hemianopia or quadrantanopia in 5 eyes ((10.2  %), ceco-
central defect in 3 eyes (6.1 %), and central scotoma in 2 
eyes (4.1 %). LHON at different stages was characterized 
by different focal visual field defects: visual field defects in 
LHON patients within 1 week after onset were mostly cen-
tral or paracentral scotoma, which was enlarged around 
the ceco-central defect, or connected to form a blind spot 
after 3–6 months. Diffuse and central isopter constriction 
defects were usually developed after 6  months. Damages 
firstly appeared in papillomacular bundle and gradually 
expanded outward. Clinical characteristics of visual field 
defects during the progression of LHON are summarized 
in Table 1 and two illustrative cases are presented in Figs. 2 
and 3. MD (dB), PSD (dB), VFI (%) mean ± SD and one-
way ANOVA at different stages are summarized in Table 2.
Discussion
LHON was firstly reported by the VonGrafe in 1858. In 
1871, the disease was named after Doctor Leber who 
discovered that LHON was an independent disease. In 
1988, Wallace DC (Wallace et al. 1988) found that LHON 
was associated with mtDNA mutation. LHON typi-
cally appears in young males with clinical manifestation 
including central vision damage and acute or subacute, 
painless, binoculus or monocular vision loss (Mulliez 
et al. 2000). Numerous studies have reported the charac-
teristics of visual field defects associated with idiopathic 
optic neuritis (ION). Marshall (1950) has detected no 
visual defects around central or paracentral scotoma 
in 90.8  % of ION cases. Trobe and Glaser (1978) have 
reported no hemianopia in 81 cases of ION, and consid-
ered hemianopia as an important indicator to differenti-
ate ION from compressive optic neuropathy. In a study 
by Keltner et  al. (1993), diffuse visual field defects are 
detected in 48.2  % of cases, whereas all other patients 
have developed focal visual field defects. Among these, 
the central scotoma only accounts for 3.8  %, including 
hemianopia and other types of visual field defects.
So far, the visual field defects due to LHON have been 
rarely reported and the characteristics of the visual field 
damage during the progression of the disease have been 
analyzed in a few papers (Newman et al. 2005, 2006), but 
these papers analyzed the visual field changes only several 
patients. Zhang et al. (2014) have detected a large central 
or paracentral scotoma at the early stage of LHON. La 
Fig. 1 Correlations between VFI, MD and BCVA (LogMAR):MD was negatively correlated with BCVA (LogMAR) (r = –0.613, p = 0.011) (line a). VFI was 
negatively correlated with BCVA (LogMAR) (r = –0.703, p = 0.000) (line c). No correlation between PSD and BCVA (Log MAR) was detected (r = 0.102, 
p = 0.577) (line b)
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Morgia et al. (2014) have described the diversity of visual 
field defects associated with LHON, but failed to ana-
lyze the characteristics of these visual field defects with 
the progress of the disease. It has also been reported that 
the scotoma or its fenestration in some LHON patients is 
relieved (Nakamura and Yamamoto 2000). A component 
of the visual improvement in LHON may be the adaptive 
phenomenon of eccentric fixation (Altpeter et al. 2013).
In this study, we found that MD and VFI were nega-
tively correlated with BCVA (LogMAR) in all tested eyes 
with or without stable BCVA (LogMAR), indicating the 
high sensitivity and stability of visual field examination 
in the diagnosis of LHON. We found that the visual 
field defects were mostly central (53.1  %) and paracen-
tral (24.5  %) scotoma at early stages of LHON. As the 
disease progressed, the visual field defects exasperated 
around the scotoma, and extended from two sides or 
enlarged surrounding the blind spot. In the late phase, 
visual field defects mainly included central isopter con-
striction (36.7 %), diffuse defects (42.9 %), hemianopia or 
quadrantanopia (10.2 %), In contrast to early stage: visual 
field defects including the nasal step and arcuate scotoma 
such as early glaucoma damage were seldom detected at 
late stages of LHON. These characteristics of visual field 
Table 1 Characteristics of visual field damage associated with LHON
Type of visual field damage These cases (percent) of visual field damage in different stages
Within 1 week From 3 to 6 months Over 6 months
Central scotoma 26 (53.1 %) 4 (8.2 %) 2 (4.1 %)
Paracentral scotoma 12 (24.5 %) 1 (2.0 %)
Blind spot enlargenment 3 (6.1 %)
Ceco-central scotoma 6 (12.2 %) 22 (44.9 %) 3 (6.1 %)
Diffuse defects 7 (14.3 %) 21 (42.9 %)
Central isopter constriction 10 (20.4 %) 18 (36.7 %)
Hemianopia or quadrantanopia 2 (4.1 %) 5 (10.2 %) 5 (10.2 %)
Fig. 2 Visual field defects found in patients with LHON (from the first to the last): characteristics of visual field damage are blind spot enlargement 
(a), paracentral scotoma (b), central scotoma (c), ceco-central scotoma (d), hemianopia (e), quadrantanopia (f), central isopter constriction (g), dif-
fuse defects (h)
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defects reported in this study might be useful for differ-
entiating the diagnosis of the disease from glaucoma.
In summary, LHON at different stages was characterized 
by different focal visual field defects: visual field defects in 
LHON patients within 1 week after onset were mostly cen-
tral or paracentral scotoma, which was enlarged around 
the ceco-central defect, or connected to form a blind spot 
after 3–6 months. Diffuse and central isopter constriction 
defects were usually developed after 6  months. Damages 
firstly appeared in papillomacular bundle and gradually 
expanded outward. These characteristics of visual field 
defects reported in this study might provide a clinical basis 
for better diagnosis of LHON. Visual field examination 
might be applied to assess the improvement of visual func-
tion in LHON patients who have received gene therapy. 
However, since LHON is a rare disease, the current study 
has been limited by the small number of cases. Further 
studies with a much larger sample size are needed to verify 
the findings in this study .
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